Studies have shown that increasing EGFR activity can over-activate downstream pro-oncogenic signaling pathways (e.g., RAS-RAF-MEK-ERK MAPK, and AKT-PI3K-mTOR pathways), which can then activate many biological outputs that may contribute to cancer cell proliferation (Wee and Wang, 2017). This evidence concerns the gene AKT1 and cancer.